Member Info for Doc.Daneeka

Not to add to the friction on here today but the chances of SNG being supported in the EU are exactly zero. We've been down this route before if LTH's can remember. The candidate list of 5 (or was it 10) therapeautics to be prioritised by the EMA. For weeks/months it was touted by the usual suspects that SNG was to be one of the candidates - nailed on - but of course we didn't get a mention. Americky is where we will find salvation.

Hi Brand "I don't know the specifics of it, but I do know SNG have offices in Ireland, Spain and if I remember correctly Brussels. Happy to be corrected on locations and can't speak to the exact eligibility for EU funding etc. "

Offices in Ireland, Spain and Bruissels ? Are you sure ?
Registrations perhaps - certainly the Irish company was establlished pre-p3 to give the company easy access to the EU but Spain ? Brussels - with actual people, sitting at actual desks, doing actual stuff. ? 3 EU officess ?
Show me what you have - staff names etc dates of appointments etc

to address the specifics of the thread - the UK has applied but so far not been acccepted for continued membership of Horizon. Disastrous if don't stay in - the French are able to block continued membership ( if they were a Bond character they'd be sitting on a Roche Bobois stroking a white moggy) UK has guaranteed application support till the end of December and pledged to continue if for some reason Johnny French keeps us out permanently

Terrible board today by the way. When Org returns to back up MrCosts you know the world's gone to sh.it

Mani on the basis that the company does not have the ability to progress the drug on its own. That its current Mcap is just a little more than Sprinter cost. Plenty of other reasons - but even if you imagine a less expensive P3 because of the specific nature of the Sprinter data - you still have to go for circa 1000 patients or risk what happened with Sprinter repeating. Any BP that commits to fund this will want a very large slice of the pie

"A collaborative trial with a partner, under the right terms, would be just as advantageous." the only way you get a collaborative trial under the right terms is if you are the senior partner in the collaboration.
Any JV would inevitably be made at a huge disadvantage to shareholders for this reason. We do need STRIVE, or RECOVER.
The wording of the last RNS or tweet (can't remember which) removed that ridiculous (if and and when appropriate) parenthethetical caveat. A Covid PT has always been the best way forward, particularly as the one in discussion is run by the same hugely resourced body that accepted SNG onto the Activ programme and was ready to progress it further on that path until Omicron emptied the hospitals. We have to believe the recent US appearances are all in support of our application to join this platform - and we know that Sprinter's deep dive showed we have better credentials than the drug that lauched the programme.
Obviously if we don't get STRIVE, but instead learn that something really clever has been happening elsewhere and the company is still able to move forward that's cool too, ( even if it takes longer and cost us more ) but NIH is still the gold standard and its STRIVE programme undoubtedly the best way forward for SNG and Synairgen.

"With respect guys this baby is worth far more than £2.25 with all the latest newsflows that hasn't as yet crystallised in the stock price.." Couple of super positive posts Elsol but we're not at 19.60 because the latest news hasn't filtered through to the market. We're here because we don't have a trial, and because none of the "weight of evidence across multiple virus types" has been proven statistically. Sprinter's data is the most compelling and we have to hope SRTIVE sees this.
It's perfectly possible that we'll be in a much better place in early 2023 but we might just as easily still be where we are now., with a promising drug that still hasn't been proven or commercialised, and a company still looking for a way forward.

truest paragraph you've ever written Tommy. The stars will either align or they won't.

In the meantime, could someone please definitively spell out the conditions for an offer - both now and after the one year anniversary of the drop.
Is it 51% or 90% or any of the suggestions we've had in between. And can the board issue more shares as a defensive action, which someone once suggested was the case.

I read it at Uni about 400 years ago Paladin so it probably is the more difficult text. My confidence in describing it at all now is probably due in large part to the awful Brad Pitt film - but I'd never admit this.

reminded me of this Python sketch for some reason. " I'm afraid I can't say the letter B....."

https://www.youtube.com/watch?v=to22rRnK7gE

rthis made me laugh Paladin "It is business as usual with sp**** early morning trading."
Wonder what happens if you write rehe****, co****, he****, ho**** or ars.e

Ah the Iliad - what a stirring tale that is. Takes a lot more effort to read Homer but the rewards are immense. The Odyssey is a little less dense - or at least the narrative flows more quickly from one setting to another - but the siege of Troy is the first great story of war.

Anosmia was a major factor from Alpha onwards but has hardly been a feature of Omicron at all - although i've read one report saying anecdotally that Drs are seeing it more with BA.5.

The top graph shows the prevalence with all of the major variants.
https://pubmed.ncbi.nlm.nih.gov/35467743/#&gid=article-figures&pid=figure-1-uid-0

It's cleary a form of endorsement from Bright and Dela Cruz. They've been paid well to attend and it's unimagineable that they'd have nothing to sayabout SNG's data. Interested to know what other drugs they'll discuss
"This panel discussion.... will highlight new discoveries that could lead to the world's first broad-spectrum antivirals, including inhaled medicines that would make emerging infections easier to treat. "

Well done Brand. Synairgen is spending its money well here, in the right location and with 2 very prestigious and specifically selected experts oin the panel. Everyone who counts should already know about SNG001 - but we've had a few of these recently and they can only be a good thing.

Strive rescues the current situation. Other scenarios add back a little value but only STRIVE gets us back in the game. A JV for Covid would have happened already as soon as the partner had convinced itself of the veracity of Sprinter's Deep dive. There may be a JV lined up for something else but we're really not a Flu trial candidate, based on what we know of that platform and COPD - huge as its potential is - will not attract a big pharma partner. LC is a possibility but they'd obviously put us on STRIVE before just trialing against LC.
If Synairgen planned to fund their own extra P3 Covid trial they'd have tried to raise the money already and catch the winter surge - so going it alone is only plausible for next year and beyond. Like Paladin though I doubt the company coul;d raise the funds for its own trial and i certainly wouldn't support it.
Still bags of potential but rather limited options if we don't get STRIVE.

Better late than never Paladin - I hope you enjoyed it as much as i have down the years. Must have been difficult to make your own image of the main characters without seeing Peter Jackson's vision. His casting was so incredible though that I quickly forgot my own teenage visions of Aragorn and co.
There may be a whimsical parallel to be found in the trilogy. Have we seen the last great battle on Pelennor Fields and is the ring about to be cast into the cracks of doom - or are we still somewhere in book 2 with Helm's Deep survived but the main travails still ahead. It feels in the West that we may be approaching the end, but we do so with a depleted armoury and the possibility that Sauron may reinvent himself again in a new and more deadly form to breach our defences.

In the East - and to abandon the analogy now -there's a potential bomb about to explode. China is locked into its lock down policy and the people have had enough . As daily cases reach 40k - (they stood at 25k a week ago) and with an under vaccinated and under exposed population (R4 said just a minute ago that 8m over 80s have not been boosted with the boosters available are of limited efficacy ) Xi knows he cannot release the restrictions or will face the possibility of potentially millions of deaths. And for the rest of us - this vulnerable under protection population may become the breeding ground for the jump from Omicron into something much worse.

I thought that was a joke Jd but blimey it's real. All this time horsing around in the lab when Maud could just have trundled her trolley thru ICU asking one lump or two. Maybe we'll get a JV with Nescafe or Costa.
Can you nebulise a Grande Caramel Machiato i wonder ? Or would you go dry and just snort the grounds ?

1 year on and 500 sub-variants later WHO has not named any further VOCs. Everything we have now comes from Omi.

" We are not disclosing the specifics of our discussions and applications with specific trials but as soon as we have a concrete trial or trials agreed we will make an announcement."

you could read this line positively if you needed cheering up on a miserable dark Thursday. Don't think they've ever mentioned applying for trials before, and it does rather suggest that applications are in. (which they bloody well ought to be )

You shd be grateful MrC. I flogged you within an inch of your life and woke up to find it deleted !!

https://vimeo.com/773463741 This is the main programme in case you missed the link on the trailer. Pulling all the snippets or profiles into one cohesive editorial feature. Synairgen's bit is at the end.
Shame it won't see the light of day in this form for ITN proper - but they have it in the bag for when something good happens with Synairgen.

I read nothing new in the latest Synairgen response - particularly not excited that they pressed send quickly. It's a slightly adjusted cut and paste job. The main difference that Platform no longer has that silly (if and when appropriate ) rider it had in the last couple of replies. As if they have something better than STRIVE or the sponsored LC or Flu trials up their sleeves. I'm certain we won't be a candidate for the influenza platform. Not until we've been approved for something else first. It looks like a companion trial for existing flu drugs and Dexa as I said a day or two ago.